Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jazz Pharmaceuticals Q4 2023 Adj EPS $5.02 Misses $5.18 Estimate, Sales $1.01B Beat $1.00B Estimate

Author: Benzinga Newsdesk | February 28, 2024 05:09pm
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.02 per share which missed the analyst consensus estimate of $5.18 by 3.09 percent. The company reported quarterly sales of $1.01 billion which beat the analyst consensus estimate of $1.00 billion by 1.12 percent. This is a 4.10 percent increase over sales of $972.12 million the same period last year.

Posted In: JAZZ


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist